{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:17:35Z","timestamp":1790612255192,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1006\/pmed.1999.0513","type":"journal-article","created":{"date-parts":[[2002,10,7]],"date-time":"2002-10-07T18:58:45Z","timestamp":1034017125000},"page":"S41-S49","source":"Crossref","is-referenced-by-count":14,"title":["Primordial Prevention of Cardiovascular Disease through Applied Genetics"],"prefix":"10.1006","volume":"29","author":[{"given":"Roger R.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/pmed.1999.0513_RF1","first-page":"79","article-title":"Gene therapy for cardiovascular disease","author":"Nabel","year":"1995"},{"key":"10.1006\/pmed.1999.0513_RF2","first-page":"97","article-title":"Gene therapy for lipid disorders","author":"Rader","year":"1995"},{"key":"10.1006\/pmed.1999.0513_RF3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00041433-199810000-00011","article-title":"Vascular gene transfer for the treatment of restenosis and atherosclerosis","volume":"9","author":"Laitinen","year":"1998","journal-title":"Curr Opin Lipidol"},{"key":"10.1006\/pmed.1999.0513_RF4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery [see comments]","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1006\/pmed.1999.0513_RF5","doi-asserted-by":"crossref","first-page":"13695","DOI":"10.1016\/S0021-9258(17)36886-2","article-title":"In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses","volume":"269","author":"Kozarsky","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1006\/pmed.1999.0513_RF6","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1073\/pnas.87.21.8437","article-title":"Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes","volume":"87","author":"Wilson","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1006\/pmed.1999.0513_RF7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ng0494-335","article-title":"Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia","volume":"6","author":"Grossman","year":"1994","journal-title":"Nat Genet"},{"key":"10.1006\/pmed.1999.0513_RF8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"key":"10.1006\/pmed.1999.0513_RF9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00000658-199602000-00002","article-title":"Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia","volume":"223","author":"Raper","year":"1996","journal-title":"Ann Surg"},{"key":"10.1006\/pmed.1999.0513_RF10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia","volume":"38","author":"Marais","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1006\/pmed.1999.0513_RF11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1345\/aph.17231","article-title":"Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias","volume":"32","author":"Yee","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1006\/pmed.1999.0513_RF12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(97)00168-8","article-title":"Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia","volume":"135","author":"Raal","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1006\/pmed.1999.0513_RF13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/adc.73.6.538","article-title":"Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia","volume":"73","author":"Gudnason","year":"1995","journal-title":"Arch Dis Child"},{"key":"10.1006\/pmed.1999.0513_RF14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0021-9150(93)90260-2","article-title":"Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia","volume":"103","author":"Feher","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1006\/pmed.1999.0513_RF15","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1006\/pmed.1999.0513_RF16","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1089\/hum.1997.8.16-1921","article-title":"Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice","volume":"8","author":"Zsigmond","year":"1997","journal-title":"Hum Gene Therm"},{"key":"10.1006\/pmed.1999.0513_RF17","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1161\/01.ATV.17.11.2532","article-title":"Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase","volume":"17","author":"Excoffon","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1006\/pmed.1999.0513_RF18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.gt.3300746","article-title":"Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors","volume":"5","author":"Fan","year":"1998","journal-title":"Gene Ther"},{"key":"10.1006\/pmed.1999.0513_RF19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.CIR.97.12.1114","article-title":"Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia","volume":"97","author":"Baumgartner","year":"1998","journal-title":"Circulation"},{"key":"10.1006\/pmed.1999.0513_RF20","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.98.25.2800","article-title":"Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia","volume":"98","author":"Losordo","year":"1998","journal-title":"Circulation"},{"key":"10.1006\/pmed.1999.0513_RF21","first-page":"I","article-title":"Safety of direct myocardial VEGF121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery","volume":"98","author":"Rosengart","year":"1998","journal-title":"Circulation"},{"key":"10.1006\/pmed.1999.0513_RF22","first-page":"205","article-title":"Gene therapy and cardiovascular disease","volume":"13","author":"French","year":"1998","journal-title":"Curr Opin Cardiol"},{"key":"10.1006\/pmed.1999.0513_RF23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/phrs.1997.0179","article-title":"Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases","volume":"35","author":"Chao","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1006\/pmed.1999.0513_RF24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.nu.09.070189.001511","article-title":"Human genetics and coronary heart disease: a public health perspective","volume":"9","author":"Hopkins","year":"1989","journal-title":"Annu Rev Nutr"},{"key":"10.1006\/pmed.1999.0513_RF25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/01.ATV.3.3.260","article-title":"Joint Distribution of lipoprotein cholesterol classes: the Framingham study","volume":"3","author":"Abbott","year":"1982","journal-title":"Arteriosclerosis"},{"key":"10.1006\/pmed.1999.0513_RF26","first-page":"47","article-title":"Guidelines for managing severe familial lipid disorders","volume":"21","author":"Williams","year":"1995","journal-title":"Primary Cardiol"},{"key":"10.1006\/pmed.1999.0513_RF27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"key":"10.1006\/pmed.1999.0513_RF28","first-page":"300","article-title":"A DNA probe for the LDL receptor gene is tightly linked to hypercholesterolemia in a pedigree with early coronary disease","volume":"39","author":"Leppert","year":"1986","journal-title":"Am J Hum Genet"},{"key":"10.1006\/pmed.1999.0513_RF29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1006\/pmed.1999.0513_RF30","first-page":"50","article-title":"Hypoalphalipoproteinemia: from a mutation to drug development","author":"Sirtori","year":"1995"},{"key":"10.1006\/pmed.1999.0513_RF31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-2275(20)41434-8","article-title":"Two apolipoprotein B gene defects in a kindred with hypobetalipoproteinemia, one of which results in a truncated variant, apoB-61, in VLDL and LDL","volume":"33","author":"Pullinger","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1006\/pmed.1999.0513_RF32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"10.1006\/pmed.1999.0513_RF33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0092-8674(94)90250-X","article-title":"Liddle's syndrome: heritable human hypertension caused by mutations in the \u03b2 subunit of the epithelial sodium channel","volume":"79","author":"Shimkets","year":"1994","journal-title":"Cell"},{"key":"10.1006\/pmed.1999.0513_RF34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jama.1995.03530140061033","article-title":"Consequences of direct genetic testing for germline mutations in the clinical manage ment of families with multiple endocrine neoplasia, type II","volume":"274","author":"Neumann","year":"1995","journal-title":"JAMA"},{"key":"10.1006\/pmed.1999.0513_RF35","first-page":"196","article-title":"Magnified risks from cigarette smoking for coronary prone families in Utah","volume":"141","author":"Hopkins","year":"1984","journal-title":"West J Med"},{"key":"10.1006\/pmed.1999.0513_RF36","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/01.ATV.15.9.1314","article-title":"Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease","volume":"15","author":"Hopkins","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1006\/pmed.1999.0513_RF37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.CIR.93.1.7","article-title":"Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations","volume":"93","author":"Jacques","year":"1996","journal-title":"Circulation"},{"key":"10.1006\/pmed.1999.0513_RF38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.HYP.32.3.393","article-title":"Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II","volume":"32","author":"Hunt","year":"1998","journal-title":"Hypertension"},{"key":"10.1006\/pmed.1999.0513_RF39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-H","article-title":"Molecular basis of human hypertension: role of angiotensinogen","volume":"71","author":"Jeunemaitre","year":"1992","journal-title":"Cell"},{"key":"10.1006\/pmed.1999.0513_RF40","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJM199406093302301","article-title":"Linkage of the angiotensinogen gene to essential hypertension","volume":"330","author":"Caulfield","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1006\/pmed.1999.0513_RF41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI118111","article-title":"Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans","volume":"96","author":"Caulfield","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1006\/pmed.1999.0513_RF42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI117083","article-title":"Angiotensinogen as a risk factor for essential hypertension in Japan","volume":"93","author":"Hata","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1006\/pmed.1999.0513_RF43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ng0593-59","article-title":"A molecular variant of angiotensinogen associated with preeclampsia","volume":"4","author":"Ward","year":"1993","journal-title":"Nature Genet"},{"key":"10.1006\/pmed.1999.0513_RF44","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/01.HYP.30.6.1331","article-title":"Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal","volume":"30","author":"Kunz","year":"1997","journal-title":"Hypertension"},{"key":"10.1006\/pmed.1999.0513_RF45","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/00004872-199312050-00019","article-title":"M235T variant of the human angiotensinogen gene in unselected hypertensive patients","volume":"11","author":"Jeunemaitre","year":"1993","journal-title":"J Hypertens"},{"key":"10.1006\/pmed.1999.0513_RF46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004872-199602000-00008","article-title":"Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity","volume":"14","author":"Hopkins","year":"1996","journal-title":"J Hypertens"},{"key":"10.1006\/pmed.1999.0513_RF47","doi-asserted-by":"crossref","first-page":"18D","DOI":"10.1016\/0002-9149(93)90006-X","article-title":"Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1006\/pmed.1999.0513_RF48","first-page":"35","article-title":"MED-PED: An integrated genetic strategy for preventing early deaths","author":"Williams","year":"1996"},{"key":"10.1006\/pmed.1999.0513_RF49","doi-asserted-by":"crossref","first-page":"75D","DOI":"10.1016\/0002-9149(93)90015-5","article-title":"Cost effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications","volume":"72","author":"Goldman","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1006\/pmed.1999.0513_RF50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1997.00440260117015","article-title":"Patients' attitudes toward detection of heterozygous familial hypercholesterolemia","volume":"157","author":"Andersen","year":"1997","journal-title":"Arch Intern Med"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743599905133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743599905133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T09:15:32Z","timestamp":1620033332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743599905133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S0091743599905133"],"URL":"https:\/\/doi.org\/10.1006\/pmed.1999.0513","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}